Lets break down the truth behind some of the most common myths surrounding GLP-1 weight loss medications
62 DabbousZAtkinSL
(JL Pharm) is established in 2012 at the beautiful West Lake Hangzhou city, China
Patent No.10,278,923 describes the use of GLP-1 peptides in oral therapy
Recommended articles Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice Pan X, Yue L, Ban J, Ren L, Chen S Journal of Inflammation Research 2022, 15:6409-6425 Published Date: 24 November 2022 Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland Hoffmann K, Michalak M, Paczkowska A Diabetes, Metabolic Syndrome and Obesity 2025, 18:2723-2738 Published Date: 7 August 2025 Integrative Mendelian Randomization and Whole-Blood Transcriptomic Analysis Implicate a MyeloidInflammation Axis in Polycystic Ovary Syndrome Fu Y, Li W, Ma L International Journal of Women's Health 2026, 18:576568 Published Date: 14 January 2026 Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study Cetiner S Diabetes, Metabolic Syndrome and Obesity 2026, 19:594898 Published Date: 31 March 2026 Dietary Antioxidant Capacity, Inflammation, and Insulin Resistance in Women with Polycystic Ovary Syndrome: An Integrated Metabolic and Nutritional Assessment Alata H, Arslan N, Keskin L, Aral C Diabetes, Metabolic Syndrome and Obesity 2026, 19:586793 Published Date: 23 May 2026
